Thanks, joining Therapeutics. interest Greg, for and morning, thanks your Edge us, as you for in good everyone. well Thank and
EG-XXXX our quarter As review the a Greg then as This improving mentioned, positive of third I'll over is to an discuss on as hemorrhage. our new of prepare progress, for for the for of outcomes be our appointment operationally time in the overview of we results. exciting then Andrew effect I'll study start will a hope we financial with for X brief NEWTON Saik Bert patients And with what Edge a hand subarachnoid call CFO. aneurysmal
of expect late is the efficacy earlier due at NEWTON unless XXXX, top results full III demonstration line preplanned the Phase readout. study by to X We data stopped a interim from study
studies outcome now was in compared fluid proposition spinal care Precisa superior study, and has our and developed hypothesis the fundamentally in site provide of results aneurysmal directly study, that of population. of patient nimodipine NEWTON discussed X,XXXx We've that development the that of the Phase transform support very into to These would oral current to the we've to with hemorrhage the EG-XXXX delivery the the both EG-XXXX delivers concentration this injury of sustained our the vulnerable nimodipine shown the the subarachnoid systemic brain of in in administered versus As II in higher of over before, platform, efficacy using directly cerebral that nimodipine. oral administration management XX EG-XXXX, brain to concentrations proprietary test to XXX days dramatically standard patient potential improve nimodipine. nonclinical
we effective improving efficacy aneurysmal the provides exposure following due outcomes that be shown suboptimal in to at although nimodipine, hemorrhage, subarachnoid to while patient believe Now drug limited oral brain.
virtually get nimodipine In similar life-threatening in EG-XXXX-type with fact, brain concentrations into it's causing potentially hypotension. oral dose-limiting impossible nimodipine without to the and
be we achieve currently top So progress. priority X regarding remain meaningful and the the we on NEWTON on quarter, the the track. study, focusing study, continued our to continues of execution In to third
was the XX NEWTON package analysis by the the their day data will that patient by Committee, call for to in the independent prespecified compiled progress analysis preparation in the the DMC. the this DMC. Monitoring DMC the the will September. triggers follow-up futility We futility study's achievement highlighted and external we Once Our first XXXth of a conduct milestone X study Data of then anticipate by This clinical XXX randomization complete study's of assessments, what the the submitted XXXX. be patients end
end for analysis penalty make there's Now a recommend results of continue communication. for the no this statistical analysis, assessment of stop one, an study to futility make study; two, the for due analysis, learn or efficacy, for futility safety the analysis of After outcomes we that unexpected futility the so can X The the X possible at public or year, doesn't this DMC any the analysis. concern. the we'll
the anticipate analysis reporting early follow-up visit first interim we the efficacy patients. top XXX of completion in of for line Now efficacy results from day formal XX upon XXXX, the
time at really to overwhelming important this, this for to there's threshold Now interim it's study for and note, want the higher a emphasize I point. that efficacy stopping
For interim nimodipine. among greater receiving in results of proportion about XX% be the the analysis from than the EG-XXXX favorable stopped absolute to to the versus patients outcomes need difference patients early, would treated be study oral
FDA application. to not in the case, full submission discuss market of to this could other data favorable Now outcomes a with the study of of in continue to this would seeking with oral versus materialize, level achieve authorities XX% and efficacy between, XXX a difference least at to health enroll patients nimodipine. absolute say, proportion we up the XX% of meet If to does the minimum
I previously in mentioned, XXXX. line the NEWTON this late full in scenario, from Phase Now expect the III results top X we study as
Now show point spoken, when clinically absolute a target our about those a the is that absolute we a is need neurointensivists. being in outcome. difference or benefit and the talked we to hundreds the around last that XX% And we've to of differences to over key meaningful years them, so, X customers, neurosurgeons
first, North the and being Australasia, NEWTON being sites drug is developed and U.S. X of and factors, Europe, discussions and neurocritical size is Phase study encouraging Track III results Phase EU So regulators. effect. saw care; leaders conducted X America, design in under Fast designations. The Israel third, NEWTON it's sample study study about in informed from NEWTON our study; XX the in II The and U.S. that neurosurgery the by three that study to detect we was designed thought with second, orphan and of at our key input the
you study may a design study patients. elements multicenter mirror III recall, as was NEWTON Phase controlled, Phase randomized, designed the we from of II XX Now which to the study, the key
We III outcome with by standard derisks to X through a patient in positive Phase approach as the So patients this the scale through nimodipine, WFNS have the GOS-E believe versus and of population and same X reproduce comparator, safety we care X. that score the of EG-XXXX for we study is, Phase an oral efficacy. the II aim had efficacy assessment same EVD, results same use That's that defined study. a and seen favorable to Xs, the
the regarding form FDA Now EG-XXXX for treatment positive, we expect application for for and the the marketing aneurysmal health gain the NEWTON EG-XXXX, hemorrhage. the of results patients. hemorrhage to and preparation In to basis of global regulatory our a study, aneurysmal continue as authorities launch for economic better -- X a we outcome other economic subarachnoid approval of burden of the a to if research potential subarachnoid the U.S. of health progresses, XX understanding
highlighting that the hospital The aneurysmal the a Meeting retrospective Care for patients Annual hemorrhage U.S. burden of claims-based per-patient economic fact, we health hospitals. charges in Society a Neurocritical presented October, data. high In showed data represent at economic poster subarachnoid new
aneurysmal In hemorrhage per-patient patients. the charges, patient patient, that had highest hospital and NEWTON aneurysmal hemorrhage study X addition, the the studied experienced subarachnoid being that's per currently $XXX,XXX the analysis all in exceeding also subarachnoid population of the showed hospitalizations longest
So are or EVD, clipping require ventricular these drain, endovascular coiling external their aneurysm. specifically, who of neurosurgical patients either an and micro repair for undergo
current segments within Now hemorrhage cost, utilization the of the also the aneurysmal we're population. treatment hemorrhage patient full with in the and subarachnoid oral nimodipine subarachnoid hemorrhage patients better continuing to understand subarachnoid
that. on we to be So of continue top
Bristol-Myers years a on represented new brings commercial in for Squibb, of she executive to readout to a our lastly, adds over operational continued of a the potentially board. and perspective at of expansion is with just of continue for team former Board on Johnson So and Johnson a & we the commercial theme XX Rose of Directors. Rose potential the expertise groundwork of as data to to a XXXX, we valuable expertise And the lay plan launch Rose commercial leadership Crane EG-XXXX. and our appointment preparing positive
address a Dr. as approach last to slightly. Precisa external Now as our Edge Annual EG-XXXX of need Meeting R. of platform would we validation Year a medical selected the recently that for of Neurological to as award approach create and believed development unmet the in And belief, the our viewed I EG-XXXX XXXX, of finalists X topic neurosurgical co-Founder, Loch community. was our When changing X major XXXX for Congress Macdonald, Innovator innovative in using started Surgeons our month. Edge to be highly during
was And CFO. truly of just joined a that can appointed Andrew here, separate validation release this make morning we're Andrew what Edge potentially do effectively Saik a we new as finally, our press trying yesterday. So this difference. again, nice we in to then announced a
successful time global multiple has of or know managing financial to areas, have operations including Andrew where Andrew Auxilium's -- value. may you successful growth CFO some from Pharmaceuticals, transactions that helped and shaping Auxilium of his the track strategy. as in commercial financial M&A record shareholder led add of helped significantly execution a leading lead he strategy, So
Andrew believe further commercialization we EG-XXXX. as So potential team plan global management for we of continue strengthens our the
Edge, of So welcome at like I'd on to everyone behalf Andrew.
words? first say would few to So to a call like and, you a Andrew, here, moment like take
